Arcutis Biotherapeutics
ARQT
ARQT
56 hedge funds and large institutions have $1.02B invested in Arcutis Biotherapeutics in 2020 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
5% more capital invested
Capital invested by funds: $974M → $1.02B (+$47.3M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Holders
56
Holding in Top 10
4
Calls
–
Puts
–
Top Buyers
| 1 | +$21.2M | |
| 2 | +$6.11M | |
| 3 | +$3.43M | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.78M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.6M |
Top Sellers
| 1 | -$12M | |
| 2 | -$1.23M | |
| 3 | -$838K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$679K |
| 5 |
CCM
CAAS Capital Management
New York
|
-$668K |